Progenics Pharmaceuticals, Inc. (PGNX) retreated with the stock falling -0.52% or $-0.05 to close at $9.62 on active trading volume of 1.64M compared its three months average trading volume of 1.07M. The Tarrytown New York 10591 based company operating under the Biotechnology industry has been trending up for the last 52 weeks, with the shares price now 97.13% up for the period and up by 11.34% so far this year. With price target of $11.8 and a 153.16% rebound from 52-week low, Progenics Pharmaceuticals, Inc. has plenty of upside potential, making it a hold with a view buy.
Progenics Pharmaceuticals, Inc. develops medicines for oncology in the United States and internationally. The company’s primary clinical-stage product candidates include Azedra, a radiotherapeutic product candidate, which is in Phase IIb clinical trial under special protocol assessment for the treatment of pheochromocytoma and paraganglioma; 1404, a technetium-99m labeled small molecule that has completed Phase II testing, as well as acts as an imaging agent to diagnose and detect prostate cancer; and PyL, a fluorinated prostate specific membrane antigen (PSMA)-targeted PET imaging agent for prostate cancer. Its clinical-stage product candidates also comprise 1095, a PSMA-targeted Iodine-131 labeled small radiopharmaceutical molecule for the treatment of metastatic castration resistant prostate cancer; PSMA antibody-drug conjugate, which has completed Phase II testing in chemotherapy-experienced patients and is ongoing second cohort in chemotherapy-naïve patients for the treatment of prostate cancer; and EXINI Bone BSI, an analytical tool for analysis of bone scan index from bone scintigraphy images. The company also offers Relistor-subcutaneous injection for the treatment of opioid induced constipation (OIC) in advanced-illness patients receiving palliative care when laxative therapy has not been sufficient; and for treatment of OIC inpatients with non-cancer pain. In addition, it develops Relistor-oral that has completed Phase III testing for the treatment of OIC; and PRO 140, which is in Phase III testing for HIV treatment. The company has license agreement with Salix Pharmaceuticals, Inc. for the development and commercialization of Relistor worldwide; and with Amgen Fremont, Inc. to use its XenoMouse technology for generating human antibodies to PSMA, as well as has collaboration agreement with Seattle Genetics, Inc. Progenics Pharmaceuticals, Inc. was founded in 1986 and is based in Tarrytown, New York.
The WhiteWave Foods Company (WWAV) had a active trading with around 1.64M shares changing hands compared to its three month average trading volume of 1.36M. The stock traded between $54.9 and $55.3 before closing at the price of $55.28 with 0.97% change on the day. The Denver Colorado 80202 based company is currently trading 51.45% above its 52 week low of $37.12 and -2.71% below its 52 week high of $56.82. Both the RSI indicator and target price of and $54.97 respectively, lead us to believe that it could rise over the coming weeks.
The WhiteWave Foods Company, a consumer packaged food and beverage company, manufactures, markets, distributes, and sells branded plant-based foods and beverages, coffee creamers and beverages, dairy products and organic salads, and fruits and vegetables in North America and Europe. It operates through three segments: Americas Foods & Beverages, Americas Fresh Foods, and Europe Foods & Beverages. The Americas Foods & Beverages segment offers plant-based foods and beverages, such as soymilk, almond milk, coconut and cashew milk, ice cream and frozen novelty products, plant-based yogurts, and Vega plant-based nutritional products under the Silk and So Delicious brands; dairy products, including Horizon Organic milk, yogurt, cheese, and other dairy products, as well as Horizon branded macaroni and cheese, and snack foods; and coffee creamers and ready-to-drink beverages under the International Delight, Dunkin Donuts, and LAND O LAKES brand names. The Americas Fresh Foods segment provides packaged salads and greens, fresh and frozen fruits and vegetables, dried fruits, and produce-based snacks under the Earthbound Farm brand. The Europe Foods & Beverages segment offers beverages using soy, almond, coconut, hazelnut, rice, oat, and other plant-based ingredients under the Alpro and Provamel brands; and plant-based alternatives to yogurt, culinary creams, desserts, and margarine. The company sells its products to grocery stores, mass merchandisers, club stores, convenience stores, and health food stores, as well as various away-from-home channels, including restaurants and foodservice outlets. It markets its products through direct sales force, independent brokers, regional brokers, and distributors, as well as through a network of partners. The WhiteWave Foods Company is headquartered in Denver, Colorado.
The Medicines Company (MDCO) saw its value increase by 2.02% as the stock gained $1.04 to finish the day at a closing price of $52.56. The stock was higher in trading and has fluctuated between $29.48-$52.66 per share for the past year. The shares, which traded within a range of $50.38 to $52.66 during the day, are up by 44.16% in the past three months and up by 42.59% over the past six months. It is currently trading 28.71% above its 20 day moving average and 39.95% above its 50 day moving average. Analysts believe the company can continue to increase in value to reach at $52.18 a share over the next twelve months. The current relative strength index (RSI) reading is 83.55.The technical indicator do not lead us to believe the stock will see more gains any time soon.
The Medicines Company provides medicines for patients in acute and intensive care hospitals worldwide. The company markets Angiomax, an intravenous direct thrombin inhibitor used as an anticoagulant in combination with aspirin in patients with unstable angina undergoing percutaneous transluminal coronary angioplasty, and for patients undergoing percutaneous coronary intervention; Cleviprex, an intravenous small molecule calcium channel blocker for blood pressure reduction; and Ionsys for the short-term management of acute postoperative pain. It also markets Kengreal, an intravenous small molecule antiplatelet agent for reducing the risk of periprocedural thrombotic events; Minocin IV, an antibiotic for the treatment of bacterial infections; Orbactiv for the treatment of acute bacterial skin and skin structure infections; and ready-to-use formulation of Argatroban for the treatment of thrombosis, as well as acute care generic products for acute cardiovascular, surgery and perioperative care, and serious infectious diseases. The company’s products under development also comprise ABP-700, an intravenous anesthetic agent for moderate or deep sedation and general anesthesia in patients undergoing diagnostic or therapeutic procedures; ALN-PCSsc for the treatment of hypercholesterolemia; Carbavance, an antibiotic agent for the treatment of hospitalized patients with gram-negative bacterial infections; and MDCO-216, a novel biologic product to reverse atherosclerotic plaque development and reduce the risk of ischemic events in patients with ACS. It has a collaboration agreement with Alnylam Pharmaceuticals, Inc,; SciClone Pharmaceuticals; and SymBio Pharmaceuticals Ltd. The Medicines Company was founded in 1996 and is based in Parsippany, New Jersey.